United States: Invalidity Of A Patent Claiming Antibodies Characterized By Their Function In View Of Amgen - Oblon, McClelland, Maier & Neustadt, L.L.P

United States: Invalidity Of A Patent Claiming Antibodies Characterized By Their Function In View Of Amgen - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq

Published

Baxalta Inc. and Baxalta GmbH (Baxalta) appealed a district court decision that the claims of U.S. Patent No. 7,033,590 were invalid for lack of enablement.

Full Article